Register
Login:
Share:
Email Facebook Twitter




Add Summit Ther to quick picks

Summit Ther Share Price (SUMM)



Share Price Information for Summit Ther (SUMM)


Share Price: 161.00Bid: 0.00Ask: 0.00Change: 0.00 (0.00%)No Movement on Summit Ther
Spread: 0.00Spread as %: 0.00%Open: 156.50High: 0.00Low: 0.00Yesterday’s Close: 161.00

Summit Therapeutics Plc Ord 1P

Summit Ther is listed in the FTSE AIM All-Share
Summit Ther is part of the Pharmaceuticals & Biotechnology sector






Share Price SpacerPrice
161.00

Share Price SpacerBid
0.00

Share Price SpacerAsk
0.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
0

Share Price SpacerOpen
156.50

Share Price SpacerHigh
0.00

Share Price SpacerLow
0.00

Share Price SpacerClose
161.00

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 61.29m £98.67m 2,000

52 Week High 185.00 52 Week High Date 2-MAR-2015
52 Week Low 107.00 52 Week Low Date 3-DEC-2014

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
0 0 0 -5.552 -29.00 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

29-Jul-15
15:01:46
155.00
85,000
Sell* 
157.00
165.00
131.75k
Trade Type:
Ordinary

31-Jul-15
17:08:38
161.00
2,500
 
157.00
165.00
4,025
Trade Type:
Ordinary

31-Jul-15
16:39:08
157.15
25,000
Sell* 
157.00
165.00
39.29k
Trade Type:
Ordinary


*Buys and Sells are calculated on the difference between the trade price and the current mid price. As such, they can occasionally be incorrect.

View more Summit Ther trades >>

Directors Deals for Summit Ther (SUMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
18-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
David Wurzer held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 David Wurzer
2.33USD7,5007500
17-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Valerie Andrews held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 Valerie Andrews
2.3USD10,50010500
16-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Frank Armstrong held the position of Non-Executive Chairman at Summit Therapeutics at the time of this trade.
 Frank Armstrong
2.34USD4,25014442
View more Summit Ther directors dealings >>

Date/Time
Author
Subject
Share Price
Opinion
Sun 15:53
GP68
gmcc
161.00
No Opinion

Good to hear from you again..was beginning to wonder where you had got to! Yes, in full agreement with your comments having watched it with interest. Not long to wait now. Have been with Summit since May 2012 and I think we have all shared the promise that this company undoubtedly has and the frustrating times that we all know about. As you say 'Good luck everyone' and yes I have good feeling about this one now!
Sun 14:14
gmcc
RE: PPMD's 2015 Connect Conference ..
161.00
No Opinion

Hi Chris - many thanks for posting that PPMD link ( courtesy algernon2) Thought , Mike Boss presentation style & delivery excellent , quite refreshing honest comments re –previous dietary issues with drug absorption etc ! This time round Phase1b patient management programme more strictly controlled , so best possible chance of positive data outcomes . Results presented by end September - not that long to wait -- fingers crossed ! Summit still offers two good chances for a very handsome investment return with both SMTC1100 & SMT19969 still very much in play ! Good luck everyone !
Sun 12:54
TIOPAT
Corrected link
161.00
No Opinion

Many thanks!
Sun 10:53
Chrisatrdg
Corrected link
161.00
Strong Buy

https://www.youtube.com/watch?v=_4NGpzIiKmU
Sun 10:52
Chrisatrdg
PPMD's 2015 Connect Conference Link
161.00
Strong Buy

Thanks to algernon2 from the other Board re: Summits presentation at the conference (hopefully DMD results next month): --------- hTTps://www.youtube.com/watch?v=_4NGpzIiKmU---------- Summit Therapeutics (C1100) [PPMD's 2015 Connect Conference]
Fri 08:30
Free-Money
Average price target $30 with...
156.50
No Opinion

... current data and analysis. This obviously all goes north on +ve clinical stage results....as expected over the coming months in both key programmes. GLA http://www.watchlistnews.com/analysts-set-30-00-target-price-for-summit-therapeutic-nasdaqsmmt/198855/ "Analysts have set a 1-year consensus target price of $30.00 for the company and are predicting that the company will post ($0.06) EPS for the current quarter, according to Zacks. Zacks has also assigned Summit Therapeutic an industry rank of 98 out of 265 based on the ratings given to its competitors. " "Several research firms have recently commented on SMMT. Oppenheimer reaffirmed an “outperform” rating and issued a $28.00 price objective on shares of Summit Therapeutic in a research note on Friday, July 10th. Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Summit Therapeutic in a research report on Friday, June 12th. Finally, JMP Securities began coverage on Summit Therapeutic in a report on Thursday, April 2nd. They set an “outperform” rating and a $32.00 price objective on the stock."

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Summit Ther (SUMM) >>
Please Login or Register to post messages






Sign up for Live Prices


CD02WL.001.081313


Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.